CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer
Published: 17 Jun 2020
Views: 572
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
Dr Melissa Johnson speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.
The CITYSCAPE trial is a randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab atezolizumab vs placebo atezolizumab in patients with PD-L1-selected NSCLC.
Dr Johnson outlines the trial design, promising results and future prospects of the CITYSCAPE study.
Related Videos
PARP inhibitors and their evolving role for the treatment of prostate cancer
Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi
24 Sep 2020
Why the ADAURA study is a big step forward for NSCLC
Dr Luis Raez - Memorial Cancer Institute, Florida, USA
17 Jul 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
30 Jun 2020
Brigatinib for NSCLC, latest research and overcoming complications
Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA
29 May 2020
PARP inhibitors for metastatic breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
7 Oct 2019
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019
Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith
30 Sep 2019
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive pa...
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
18 Apr 2019
ASCO GU 2019 renal highlights
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
14 Feb 2019
